Statins are a class of drugs that lower cholesterol and thereby reduce the risk of heart disease and stroke. They work by preventing the synthesis of low-density lipoprotein (LDL or “bad cholesterol”) in the liver and promoting its clearance from the blood. They are the most effective cholesterol-lowering drugs currently available and are the cornerstone of the National Heart, Lung, and Blood Institute’s National Cholesterol Education Program (NCEP) treatment guidelines.
The NCEP recommends a “treat-to-target” strategy, in which patients are given specific statin doses to achieve a desired level of LDL cholesterol in the blood. In this case, low LDL cholesterol is the “target.” Yet some physicians are questioning whether treating to any target is the best approach to fighting disease. A recent study in the Annals of Internal Medicine suggests that “tailored treatment”, an approach attempts to practice personalized medicine by estimating three factors, is more effective than a treat-to-target strategy [1].